|

XELOX Clinical Trials

12 actively recruiting trials across 1 location

Also known as: Capecitabine and Oxaliplatin, oxaliplatin and capecitabine

Other11 trials

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Phase 2
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Phase 2
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/2
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Phase 3
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Phase 2
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Phase 1
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
Phase 2
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Phase 3
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
Phase 3
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
Phase 2

Los Angeles, California1 trial

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.